Brepocitinib Overview & RVT-3101 Update

Key Catalysts Program Vant Catalyst VTAMA (tapinarof) cream Updates on commercial launch of VTAMA in psoriasis Expected Timing Roivant pipeline growth r LNP platform ३ ли New mid/late-stage in-licensing announcements Updates to LNP patent litigation Roivant Discovery Updates on discovery programs and technology Ongoing Ongoing Ongoing Ongoing VTAMA (tapinarof) cream Topline data from Phase 3 trials in atopic dermatitis 1H 2023 IMVT-1402 Y Initial data from Phase 1 trial Mid 2023 RVT-3101 r Final data from Phase 2B trial in ulcerative colitis 1H 2023 Brepocitinib Topline data from potentially registrational Phase 2B trial in systemic lupus erythematosus 2H 2023 Batoclimab Y Initial data from Phase 2 trial in Graves' disease 2H 2023 RVT-2001 Batoclimab Data from RVT-2001 Phase 1/2 trial in lower-risk myelodysplastic syndrome Initial data from pivotal Phase 2B trial in chronic inflammatory demyelinating polyneuropathy 2H 2023 1H 2024 Namilumab n Topline data from Phase 2 trial in sarcoidosis 1H 2024 Batoclimab A Topline data from Phase 3 trial in myasthenia gravis 2H 2024 Batoclimab Y Topline data from Phase 3 trials in thyroid eye disease Topline data from Phase 3 trial in dermatomyositis 1H 2025 2025 Brepocitinib roivant All catalyst timings are based on current expectations and, where applicable, contingent on FDA feedback, and may be subject to change. All timelines reference calendar years. 28 For investor audiences only

View entire presentation